XNCR - Xencor, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.91
+1.43 (+4.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.48
Open35.49
Bid36.83 x 800
Ask36.85 x 800
Day's Range35.28 - 37.44
52 Week Range27.75 - 46.33
Volume436,834
Avg. Volume598,471
Market Cap2.041B
Beta (3Y Monthly)1.24
PE Ratio (TTM)43.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Celia Eckert as vice president, general counsel and corporate secretary. Ms. Eckert brings more than 20 years of experience as a corporate attorney in both law firm and in-house roles. At Xencor she will be responsible for all legal matters, including transactions, corporate governance and employment law, as well as overseeing the Company’s intellectual property portfolio.

  • Business Wire

    Xencor Reports Second Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today --

  • Business Wire

    Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle

  • Business Wire

    Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor, plans to retire from Xencor effective October 31, 2019, following a transition period with a successor.

  • PR Newswire

    MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:   S&P MidCap 400 constituent MarketAxess Holdings Inc. ...

  • Business Wire

    Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in a Phase 1 clinical study to evaluate the safety and tolerability of XmAb22841, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors. XmAb22841 is a bispecific antibody that simultaneously targets the immune checkpoint receptors CTLA-4 and LAG-3.

  • Business Wire

    Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business development. Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.

  • Business Wire

    Xencor Reports First Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today --

  • Business Wire

    Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody that simultaneously targets the immune receptors PD-1 and ICOS, for the treatment of patients with advanced solid tumors.

  • Business Wire

    Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.

  • Business Wire

    Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that was placed on the Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. “We are working with investigational sites to resume enrollment based on the amended protocol, through which we have sought to enhance the safety of patients participating in the study,” said Paul Foster, M.D., senior vice president and chief medical officer at Xencor.

  • Business Wire

    Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. Xencor and Astellas will collaborate to generate bispecific antibodies directed toward a selected anti-tumor target for the potential treatment of patients with cancer, and Astellas will have an exclusive worldwide license to develop and commercialize novel drug candidates.

  • Business Wire

    Xencor to Participate in Upcoming Investor Conferences

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle

  • Business Wire

    Xencor Announces Closing of Research Collaboration and License Agreement with Genentech

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Xencor and Genentech entered the agreement to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306, an IL-15/IL-15Rα cytokine complex engineered with Xencor’s bispecific Fc domain and Xtend™ Fc technology.

  • GlobeNewswire

    New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire

    Xencor Reports Fourth Quarter and Full Year 2018 Financial Results

    - Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA ...

  • ACCESSWIRE

    Xencor, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Xencor, Inc. (NASDAQ: XNCR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 PM Eastern ...

  • PR Newswire

    Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045

    MONROVIA, Calif., Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. No new patients will be allowed to enroll in the study until the partial clinical hold is lifted by the FDA.

  • PR Newswire

    Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019

    MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...

  • PR Newswire

    Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

    MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306. XmAb24306 is an IL-15/IL-15Rα cytokine complex engineered with Xencor's bispecific Fc domain and Xtend™ Fc technology and is Xencor's most advanced preclinical cytokine program.

  • GlobeNewswire

    Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire

    Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody

    MONROVIA, Calif., Jan. 7, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today announced it will regain rights to develop and commercialize XmAb13676, a CD20 x CD3 bispecific antibody, from Novartis effective June 20, 2019, due to strategic pipeline reprioritization by Novartis. Xencor granted Novartis co-development and ex-U.S. commercial rights in June 2016 through a collaboration and license agreement to develop and commercialize novel bispecific antibodies, including XmAb13676 and XmAb14045, and to access Xencor's XmAb® bispecific Fc and other Fc technologies.